Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01736943 · ClinicalTrials.gov registry record · Phase 2
Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia
A Phase 2 study, sponsored by Joseph Tuscano.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01736943 is a Phase 2 study that has completed, run by Joseph Tuscano. The registered enrollment target is 25 participants.
The verdict
NCT01736943, a Phase 2 study, has completed, sponsored by Joseph Tuscano.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether bortezomib in combination with doxil/lipodox is effective in the treatment of Acute Myeloid Leukemia.
Interventions
- DRUG Doxil
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2012-12-19 |
| Est. Completion | 2019-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01736943
The ClinicalTrials.gov registry entry for NCT01736943 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joseph Tuscano, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Doxil is the first listed.
NCT01736943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01736943 about?
NCT01736943 is a clinical study titled "Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia". The purpose of this study is to determine whether bortezomib in combination with doxil/lipodox is effective in the treatment of Acute Myeloid Leukemia.
What is the current status of trial NCT01736943?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2012-12-19. Estimated completion is 2019-05-20.
What interventions are being tested in trial NCT01736943?
The interventions under investigation include: Doxil (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT01736943?
This trial is sponsored by Joseph Tuscano, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.